...
首页> 外文期刊>American Journal of Hematology >Prognostic significance of high hyperdiploid and triploid/tetraploid adult acute myeloid leukemia
【24h】

Prognostic significance of high hyperdiploid and triploid/tetraploid adult acute myeloid leukemia

机译:高二倍体和三倍体/四倍体成人急性髓性白血病的预后意义

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

To ascertain the clinical implications of high hyperdiploid (HH; 49-65 chromosomes) and triploid/tetraploid (TT; >65 chromosomes) adult acute myeloid leukemia (AML), all such cases were retrieved from the Swedish AML Registry. Of the 3,654 cytogenetically informative cases diagnosed between January 1997 and May 2014, 68 (1.9%) were HH (n=50)/TT (n=18). Patients with HH/TT were older than those with intermediate risk (IR) AML (median 71 years vs. 67 years; P=0.042) and less often had de novo AML (63% vs. 79%; P=0.004); no such differences were observed between HH/TT and complex karyotype (CK) AML. The overall survival (OS) was similar between patients with HH/TT and CK AML (median 0.9 years vs. 0.6 years; P=0.082), whereas OS was significantly longer (median 1.6 years; P=0.028) for IR AML. The OS was shorter for cases with HH than with TT (median 0.6 years vs. 1.4 years; P=0.032) and for HH/TT AMLs with adverse abnormalities (median 0.8 years vs. 1.1 years; P=0.044). In conclusion, HH/TT AML is associated with a poor outcome, but chromosome numbers >65 and absence of adverse aberrations seem to translate into a more favorable prognosis. Thus, HH/TT AMLs are clinically heterogeneous and should not automatically be grouped as high risk.Am. J. Hematol. 90:800-805, 2015. (c) 2015 Wiley Periodicals, Inc.
机译:为了确定高双倍体(HH; 49-65个染色体)和三倍体/四倍体(TT;> 65个染色体)成人急性髓细胞性白血病(AML)的临床意义,所有此类病例均从瑞典AML注册中心检索。在1997年1月至2014年5月之间诊断的3,654例细胞遗传学信息病例中,有68例(1.9%)为HH(n = 50)/ TT(n = 18)。患有HH / TT的患者年龄大于患有中等风险(IR)AML的患者(中位年龄为71岁vs. 67岁; P = 0.042),而从头进行AML的患者较少(63%vs. 79%; P = 0.004)。在HH / TT与复杂核型(CK)AML之间未观察到此类差异。患有HH / TT和CK AML的患者的总生存期(OS)相似(中位0.9年vs. 0.6年; P = 0.082),而IR AML的OS明显更长(中位1.6年; P = 0.028)。伴有HH的患者的OS短于TT(中位0.6年vs. 1.4年; P = 0.032)和伴有不良异常的HH / TT AMLs(中位0.8年vs.1.1年; P = 0.044)。总之,HH / TT AML与不良预后相关,但染色体数> 65和无不良像差似乎可以预示更佳的预后。因此,HH / TT AML在临床上是异质的,不应自动归类为高风险。 J. Hematol。 90:800-805,2015.(c)2015威利期刊公司

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号